Erasca, Inc. financial data

Symbol
ERAS on Nasdaq
Industry
Pharmaceutical Preparations
Location
10835 Road To The Cure, Suite 140, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.24K % +4.27%
Debt-to-equity 20.8 % -8.8%
Return On Equity -42.3 % +31.3%
Return On Assets -35 % +30.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 283M shares +87.1%
Common Stock, Shares, Outstanding 283M shares +87.8%
Entity Public Float 297M USD -31.2%
Common Stock, Value, Issued 28K USD +86.7%
Weighted Average Number of Shares Outstanding, Basic 282M shares +87.7%
Weighted Average Number of Shares Outstanding, Diluted 282M shares +87.7%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 41.2M USD +10.3%
Operating Income (Loss) -178M USD +27.7%
Nonoperating Income (Expense) 18.6M USD +23%
Net Income (Loss) Attributable to Parent -159M USD +31%
Earnings Per Share, Basic -0.83 USD/shares +51.7%
Earnings Per Share, Diluted -0.83 USD/shares +51.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 68.9M USD -39%
Marketable Securities, Current 250M USD +36%
Cash, Cash Equivalents, and Short-term Investments 319M USD +7.48%
Assets, Current 330M USD +7.91%
Property, Plant and Equipment, Net 17.2M USD -26.2%
Operating Lease, Right-of-Use Asset 32.9M USD -14.6%
Other Assets, Noncurrent 3.88M USD -11.6%
Assets 529M USD +26.1%
Accounts Payable, Current 2.41M USD -35%
Liabilities, Current 30M USD +12.3%
Operating Lease, Liability, Noncurrent 48.5M USD -8.41%
Other Liabilities, Noncurrent 340K USD -55.3%
Liabilities 78.9M USD -1.96%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.83M USD
Retained Earnings (Accumulated Deficit) -735M USD -27.6%
Stockholders' Equity Attributable to Parent 450M USD +32.8%
Liabilities and Equity 529M USD +26.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -33.3M USD -26.2%
Net Cash Provided by (Used in) Financing Activities 6.93M USD +3687%
Net Cash Provided by (Used in) Investing Activities 9.97M USD -32.2%
Common Stock, Shares Authorized 800M shares 0%
Common Stock, Shares, Issued 283M shares +87.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -16.3M USD -42.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 69.3M USD -38.8%
Deferred Tax Assets, Valuation Allowance 144M USD +10.5%
Deferred Tax Assets, Gross 156M USD +6.13%
Operating Lease, Liability 52.9M USD -6.73%
Payments to Acquire Property, Plant, and Equipment 42K USD -96.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -157M USD +31.8%
Lessee, Operating Lease, Liability, to be Paid 74M USD -10.5%
Property, Plant and Equipment, Gross 26.3M USD -10.8%
Operating Lease, Liability, Current 4.45M USD +16.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 9.17M USD +1.62%
Lessee, Operating Lease, Liability, to be Paid, Year One 9.02M USD +3.11%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 21M USD -18.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 9.2M USD +0.32%
Deferred Tax Assets, Operating Loss Carryforwards 59.3M USD +13.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 80M shares 0%
Unrecognized Tax Benefits 4.1M USD +50.3%
Lessee, Operating Lease, Liability, to be Paid, Year Four 9.28M USD +0.85%
Operating Lease, Payments 2.1M USD +143%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 3.88M USD +4.27%
Share-based Payment Arrangement, Expense 26.8M USD +5.21%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%